REFERENCES
- Anderson DE, Bedzioch MD. Familiar breast cancer risk. Cancer 1993; 72: 114–9.
- Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. USA 1997; 68: 820–3.
- Knudson AG. Hereditary cancer: two hits revisited. J. Cancer Res. Clin. Oncol. 1996; 122: 135–40.
- Kinzler WK, Vogelstein B. Gatekeepers and caretakers. Sci-ence 1997; 386: 761–3.
- Narod SA. Hereditary breast carcinoma syndromes. Cancer 1997; 80: 537–56.
- Li FP, Garber JE, Fried FH, et al. Recommendation of predictive testing for germ line p53 mutations among cancer-prone individuals. J. Natl. Cancer Inst. 1992; 84: 1156–60.
- Starink TM, van der Veen JPW, Arwent F, et al. The Cowden syndrome: a clinical and genetic study in 21 patients. Clin. Genet. 1986; 29: 222–33.
- Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer 1996; 77: 2318–24.
- Ford D, Easton DF, Bishop DT, Narod SA, Goldgar UK. Breast cancer linkage consortium. Risks of cancer in BRCA-1 mutation carriers. Lancet 1994; 343: 692–5.
- Courch FJ, DeShano ML, Blackwook MA, et al. BRCA 1 mutations in women attending clinics that evaluate the risk of breast cancer. N. Engl. J. Med. 1997; 336: 1409–15.
- Kaufman DJ, Tucker MA, Struewing JP. Breast and ovarian cancer penetrance in a historical cohort of BRCA1 carriers. Abstract. 21st Annual San Antonio Breast Cancer Sympo-sium 1998.
- Thorlacius S, Struewing JP, Hartge P, et al. Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 1998; 352: 1337–9.
- Lapham EV, Kozma C, Weiss JO. Genetic discrimination: perspectives of consumers. Science 1996; 274: 621.
- Croyle RT, Achilles JS, Lerman C. Psychologic aspects of cancer genetic testing. Cancer 1997; 80: 569–74.
- Peters JA, Biesecker BB. Genetic counseling and hereditary cancer. Cancer 1997; 80:576
- Lalloo F, Boggis CRM, Evans DGR, Shenton A, Threlfall AG, Howell A. Screening by mammography, women with a family history of breast cancer. Eur. J. Cancer 1998; 34: 937–40.
- Burke W, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. JAMA 1997; 277: 997–1003.
- Eeles JWR, Cole T, Taylor R, Lunt P, Baum M. Prophylactic mastectomy for genetic predisposition to breast cancer: The proband's story. Clin. Oncol. 1996; 8: 222–5.
- Struewing JP, Watson P, Easton DF, Ponder BA, Lynch HT, Tucker MA. Effectiveness of prophylactic oophorectomy in inherited breast/ovarian cancer families, Am J Hum Genet 1995; 55: A70 no 384.
- Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the national surgical adjuvant breast and bowel project P-1 study. J. Natl. Cancer. Inst. 1998; 90: 1371–88.
- Breast Cancer Lineage Consortium. Pathology of familiar breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 1997; 349: 1505–10.
- Johansson OT, Idvall I, Anderson C, et al. Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur. J. Cancer 1997; 33: 362–71.
- Johansson OT, Ranstam J, Borg /k, Olsson H. Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J. Clin. Oncol. 1998; 16: 397–404.